A new heart pump from Abiomed was found to reduce deaths in severe heart attack patients in a recent trial presented at the American College of Cardiology conference. The trial followed 355 patients for 180 days, with half receiving the heart pump and the other half receiving standard care. Results showed that 46% of patients in the device group died compared to 59% in the standard care group. However, 24% of patients in the device group experienced complications such as serious bleeding and kidney therapy, compared to only 6% in the control group. This study highlights the potential benefits and risks of using this heart pump.
Source link
J&J’s Abiomed heart pump reduces heart attack deaths in trial
